Form 4: Conduit Pharmaceuticals Director Faith L. Charles Reports Acquisition and Disposal of Common Stock

Director Faith L. Charles reports acquiring 46,629 shares and disposing of shares of Conduit Pharmaceuticals common stock on March 30, 2025.

Summary

• On March 30, 2025, Faith L. Charles, a director of Conduit Pharmaceuticals Inc., acquired 46,629 shares of common stock at a price of $0.89 per share.
• These shares were issued under the 2023 Stock Incentive Plan, in lieu of $41,500 in accrued cash retainers from the Non-Employee Director Compensation Program.
• Following this transaction, Charles beneficially owns 50,044 shares of Conduit Pharmaceuticals.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of shares by a director can be seen as a slightly positive sign, but it's primarily related to compensation.

Positives

• Director's acquisition of shares may signal confidence in the company.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• Employees may view the director's stock acquisition as a positive sign for the company.

Key Dates

Keywords

Form 4, Beneficial Ownership, Director, Conduit Pharmaceuticals, CDT, Stock Incentive Plan, Faith L. Charles, Common Stock